6533b85efe1ef96bd12bf495
RESEARCH PRODUCT
Drug-Eluting Stent for Left Main Coronary Artery Disease
Sebastiano MarraPaweł BuszmanAntonio ColomboPiera CapranzanoCorrado TamburinoYoung-hak KimMarie Claude MoriceJean FajadetDavide CapodannoMarco ValgimigliOttavio AlfieriThierry LefèvreIgor F. PalaciosMartin B. LeonRoxana MehranAzeem LatibRaj MakkarAlaide ChieffoSeung-jung ParkSanda JegereChristoph NaberAndrejs ĒRglisYoshinobu OnumaArvind K. AgnihotriPatrick W. SerruysJeffrey W. MosesEmanuele MeligaRonan MargeyImad SheibanTarun Chakravartysubject
medicine.medical_specialtybusiness.industrymedicine.medical_treatmentHazard ratioPercutaneous coronary interventionEuroSCOREmedicine.diseaseSurgeryCoronary artery diseasesurgical procedures operativeDrug-eluting stentAngioplastyInternal medicineConventional PCImedicineCardiologycardiovascular diseasesMyocardial infarctionbusinessCardiology and Cardiovascular Medicinedescription
Objectives The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort. Results In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95% CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95% CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p Conclusions In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.
year | journal | country | edition | language |
---|---|---|---|---|
2012-07-01 | JACC: Cardiovascular Interventions |